Navigation Links
Sanofi Pasteur announces FDA approval of menactra meningococcal conjugate vaccine indication for infants
Date:4/25/2011

Swiftwater, PA April 22, 2011 - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to include a two-dose schedule for infants and children 9 months through 23 months of age. This is the first U.S. approval of a meningococcal vaccine for this age group.

"Licensure of Menactra vaccine for infants as young as 9 months of age gives the opportunity to help protect infants against this potentially deadly disease when the likelihood of exposure supports a need for early protection," said Stephen I. Pelton, MD, Professor of Pediatrics and Epidemiology, Boston University Schools of Medicine and Public Health and Chief, section of Pediatric Infectious Diseases, Boston Medical Center.

Meningococcal disease is a rare but deadly disease caused by the bacterium Neisseria meningitidis. The disease can progress quickly and take the life of a child within 24 hours. Menactra vaccine was the first quadrivalent conjugate vaccine licensed in the United States for active immunization against meningococcal disease caused by the serogroups contained in the vaccine (A, C, Y and W-135). More than 36 million doses of Menactra vaccine have been distributed in the United States since its licensure in 2005.

The FDA approval of Menactra vaccine for infants was based on results of one Phase II and three Phase III modified single-blind, controlled, multicenter trials in which more than 3,300 infants from the United States received Menactra vaccine using a two-dose schedule, starting as young as 9 months of age. Results from these studies showed that 2 doses of Menactra vaccine given 3 months apart elicit a robust immune response against the serogroups included in the vaccine. The studies also showed that measles-mumps-rubellavaricella vaccine (MMRV) and pneumococcal conjugate vaccine (PCV7) can be administrated concomitantly with Menactra vaccine in children. Vaccine related reactions included swelling, tenderness at injection site, and irritability.

"The approval of Menactra vaccine for infants is a significant advancement toward potentially eliminating the threat of this serious disease in this vulnerable population for included serogroups," said Michael Decker, MD, MPH, vice president, scientific and medical affairs at Sanofi Pasteur. "With this approval, it is now possible to help protect persons from 9 months through 55 years of age."


'/>"/>

Contact: Amy Ba
Amy.ba@sanofipasteur.com
570-957-0717
Cooney Waters Group, Inc.
Source:Eurekalert

Related medicine news :

1. Eggs Being Produced by Recall Farms Safe, if Pasteurized, Experts Say
2. Government of Canada announces results in fight to save women and children with malaria
3. Oxford Nanopore announces licence agreement with Harvard University for graphene DNA sequencing
4. Elsevier Health Middle East announces publication of first bilingual medical title
5. International Vaccine Institute announces launch of Dengue Vaccine Initiative
6. Washington Life Sciences Discovery Fund announces grants to commercialize promising technologies
7. MSD Wellcome Trust Hilleman Laboratories announces first project
8. AIUM announces ultrasound practice accreditation in fetal echocardiography
9. American Physical Society announces Physical Review X
10. Beth Israel Deaconess Medical Center announces new AAAS Fellows
11. NARSAD announces $12.6 million for new generation of brain and behavior research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... (PRWEB) , ... June 24, 2017 , ... ... in Erie, PA at the Sheraton Erie Bayfront and Erie Convention Center on ... based medicine experience, exhibits, a student quiz bowl, award and scholarship presentations, and ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... needed and will ultimately do significant harm to people with all chronic conditions, ... , "While it leaves in place the Affordable Care Act (ACA) requirement that ...
(Date:6/23/2017)... ... 23, 2017 , ... Dr. Ran Y. Rubinstein , ... begun offering three new minimally invasive procedures to patients who want a younger ... Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet rich plasma ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ensuring meat products have ... highlight the importance of correctly using a meat thermometer. The videos feature University ... research on consumer food safety habits. Dr. Bruhn explains the variety of meat ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance Agency ( ... Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more people than ... Biggert-Waters Act was enacted to reflect the actual risk in flood zone areas ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... 19, 2017  Researchers from DRUGSCAN ® and ... host a live, complimentary webinar titled, "Untangling methods to ... the real world" on Wednesday June 28, 2017 from ... This webinar will feature interviews with recreational and dependent ... manipulation techniques abusers use to prepare opioid tablets for ...
(Date:6/16/2017)... BOSTON , June 16, 2017  Exactly 50 years ... kicked off what later became known as the San Francisco ... www.northernlight.com ) is unveiling two radical innovations in strategic market ... summer.  This announcement marks the beginning of Northern Light,s "Summer ... ...
(Date:6/14/2017)... 14, 2017 The Bio Supply Management Alliance ... of Fremont and the Biomedical Manufacturing Network ... in California by providing a ... and fostering workforce development. The primary focus of this ... start-ups, as well as small and mid-sized biomedical companies. ...
Breaking Medicine Technology: